Yardley, Pa.-based OptiNose Inc. is planning a public offering of 4.5 million common shares.
The company will offer 2,250,000 shares, while 2,250,000 shares will be offered by certain selling stockholders.
OptiNose and the selling stockholders are expected to give the underwriters an option to buy an additional 675,000 shares.
The pharmaceutical company will not receive any proceeds from the sale of shares by the selling stockholders.
Jefferies and Piper Jaffray will serve as the lead joint book-running managers, BMO Capital Markets and RBC Capital Markets will act as joint book-running managers, and Cantor will act as sole lead manager for the offering.
OptiNose is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat specialists and allergy specialists in the U.S.
